Stanford PhD Candidate Creates Platform for Parkinson’s Disease Patients to Share Their Story with Researchers

"Beyond research motivation, I want to give a voice to the disease to help researchers empathize and further understand who all their hard work is going toward." These are words from…

Continue Reading Stanford PhD Candidate Creates Platform for Parkinson’s Disease Patients to Share Their Story with Researchers
Extension Study for Prader-Willi Syndrome Initiated After Completion of Phase 2a Trial
source: pixabay.com

Extension Study for Prader-Willi Syndrome Initiated After Completion of Phase 2a Trial

Prader-Willi Syndrome (PWS) is caused by deleted genes on chromosome 15. This results in improper signaling of satiety, leading to obesity. Individuals with the condition can suffer from respiratory/cardiac disease, gastric…

Continue Reading Extension Study for Prader-Willi Syndrome Initiated After Completion of Phase 2a Trial

Positive Results From a Phase IIb Trial of Firdapse for MuSK Myasthenia Gravis Published Online

Myasthenia Gravis (MG) is a progressive autoimmune disorder which results in the weakening of muscles. Most people with the condition are able to manage their symptoms with treatment and have…

Continue Reading Positive Results From a Phase IIb Trial of Firdapse for MuSK Myasthenia Gravis Published Online

Potential Gene Therapy for Limb Girdle Muscular Dystrophy Type 2D Granted Orphan Drug Designation

Limb Girdle Muscular Dystrophy Type 2D (LGMD2D), also called alpha-sarcoglycanopathy, is a form of muscular dystrophy which is caused by a defected SGCA gene. It causes the body to lose function of…

Continue Reading Potential Gene Therapy for Limb Girdle Muscular Dystrophy Type 2D Granted Orphan Drug Designation
Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients
Source: Pixabay

Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients

Thanks to a Phase 2 trial, pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Ph+ ALL, now have a new treatment option. The FDA has announced approval of Sprycel…

Continue Reading Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients

Orphan Drug Designation Given for Potential New Treatment for C3 Globerulopathy

Apellis Pharmaceuticals has just announced that they have received Orphan Drug Designation from the FDA for APL-2, a C3 complement inhibitor. The company is currently investigating the drug as a…

Continue Reading Orphan Drug Designation Given for Potential New Treatment for C3 Globerulopathy

Making Strides Towards New Treatment Options for Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis (NASH), is condition most commonly caused by obesity or type 2 diabetes. It can result in fibrosis, complications in the lung and cardiac system, liver cancer, liver cirrhosis,…

Continue Reading Making Strides Towards New Treatment Options for Nonalcoholic Steatohepatitis

Kinetic Kids Provides Kids with Cerebral Palsy and Other Conditions the Chance to Play on a Team

Kinetic Kids is a nonprofit which was originally formed to keep children who needed physical therapy active outside of their actual physical therapy sessions by giving them the opportunity to…

Continue Reading Kinetic Kids Provides Kids with Cerebral Palsy and Other Conditions the Chance to Play on a Team